Inhibrx (INBX) Stock Forecast, Price & News

4 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Inhibrx in the last year. There are currently 4 buy ratings for the stock. The consensus among Wall Street analysts is that investors should "buy" INBX shares.
View INBX analyst ratings or view top-rated stocks.

4 analysts have issued 12 month target prices for Inhibrx's stock. Their INBX share price forecasts range from $35.00 to $60.00. On average, they expect the company's share price to reach $47.00 in the next year. This suggests a possible upside of 100.9% from the stock's current price.
View analysts price targets for INBX or view top-rated stocks among Wall Street analysts.

Inhibrx's stock was trading at $24.64 at the start of the year. Since then, INBX shares have decreased by 5.1% and is now trading at $23.39.
View the best growth stocks for 2023 here.

The company is scheduled to release its next quarterly earnings announcement on Monday, August 14th 2023.
View our INBX earnings forecast.

Inhibrx, Inc. (NASDAQ:INBX) issued its earnings results on Tuesday, November, 9th. The company reported ($0.54) earnings per share for the quarter, topping the consensus estimate of ($0.60) by $0.06. The firm had revenue of $2.53 million for the quarter, compared to analysts' expectations of $1 million. Inhibrx had a negative trailing twelve-month return on equity of 1,961.44% and a negative net margin of 12,725.62%.

ETFs with the largest weight of Inhibrx (NASDAQ:INBX) stock in their portfolio include Loncar Cancer Immunotherapy ETF (CNCR), Virtus LifeSci Biotech Clinical Trials ETF (BBC), SPDR S&P Biotech ETF (XBI), Direxion Daily S&P Biotech Bull 3x Shares (LABU), Principal Healthcare Innovators ETF (BTEC), iShares Micro-Cap ETF (IWC), iShares Biotechnology ETF (IBB) and ProShares Ultra Nasdaq Biotechnology (BIB).

Based on aggregate information from My MarketBeat watchlists, some companies that other Inhibrx investors own include Advanced Micro Devices (AMD), Trevena (TRVN), Vivint Solar (VSLR), Activision Blizzard (ATVI), Daqo New Energy (DQ), Fastly (FSLY), Innovative Industrial Properties (IIPR), Lovesac (LOVE) and Micron Technology (MU).

(INBX) raised $102 million in an IPO on Wednesday, August 19th 2020. The company issued 6,000,000 shares at $16.00-$18.00 per share. Jefferies, Evercore ISI and Credit Suisse served as the underwriters for the IPO and LifeSci Capital was co-manager.

Inhibrx trades on the NASDAQ under the ticker symbol "INBX."

Inhibrx's stock is owned by many different institutional and retail investors. Top institutional investors include Perceptive Advisors LLC (8.29%), BlackRock Inc. (5.35%), State Street Corp (4.76%), FMR LLC (3.69%), ArrowMark Colorado Holdings LLC (2.16%) and Geode Capital Management LLC (1.40%). Insiders that own company stock include Brendan P Eckelman, Global Investors Lp Viking, Jon Faiz Kayyem and Mark Lappe.
View institutional ownership trends.

Shares of INBX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

One share of INBX stock can currently be purchased for approximately $23.39.

Inhibrx (NASDAQ:INBX) has a market capitalization of $1.02 billion and generates $2.19 million in revenue each year. The company earns $-145,230,000.00 in net income (profit) each year or ($3.94) on an earnings per share basis.

The company employs 132 workers across the globe.

Inhibrx's mailing address is 11025 N. TORREY PINES ROAD SUITE 200, LA JOLLA CA, 92037. The official website for the company is www.inhibrx.com. The company can be reached via phone at 858-795-4220 or via email at amy@juniper-point.com.